Loading...
|
Please use this identifier to cite or link to this item:
https://ir.csmu.edu.tw:8080/ir/handle/310902500/20472
|
| Title: | Inhibition of human lung adenocarcinoma growth and metastasis by JC polyomavirus-like particles packaged with an SP-B promoter-driven CD59-specific shRNA |
| Authors: | Lin, M.-C.
Shen, C.-H.
Chang, D.
Wang, M. |
| Contributors: | 中山醫大附設醫院 |
| Keywords: | CD59;gene therapy;JCPyV VLPs;lung adenocarcinoma;SP-B promoter |
| Date: | 2019-11 |
| Issue Date: | 2019-11-21T04:00:33Z (UTC)
|
| Publisher: | Clinical science (London, England : 1979) |
| ISSN: | 14708736 |
| Abstract: | Lung cancer ranks first in both incidence and mortality and is a major health concern worldwide. Upon recognition of specific antigens on tumor cells, complement-dependent cytotoxicity (CDC) is activated, arresting cell growth or inducing apoptosis. However, by overexpressing CD59, a membrane complement regulatory protein (mCRP), lung cancer cells develop resistance to CDC. We previously showed that virus-like particles (VLPs) of human JC polyomavirus (JCPyV) could be used as a gene therapy vector to carry a suicide gene expression plasmid with a lung-specific promoter (SP-B (surfactant protein B)) for lung adenocarcinomas. Herein, we designed a CD59-specific short hairpin RNA (shRNA) expression plasmid driven by SP-B (pSPB-shCD59) to effectively and specifically inhibit CD59 overexpression in lung cancer cells. Treatment of lung cancer cells in vitro with JCPyV VLPs containing pSPB-shCD59 (pSPB-shCD59/VLPs) induces CDC and death of cancer cells. Mice that were subcutaneously injected with human lung cancer cells showed an 87% inhibition in tumor growth after tail vein injection of pSPB-shCD59/VLPs. Moreover, in a mouse model of lung cancer metastasis, a reduction in the lung weight by 39%, compared with the control group, was observed in mice treated with pSPB-shCD59/VLPs after tail vein injection of human lung cancer cells. Furthermore, tissue sectioning showed that the number and size of tumors produced was significantly reduced in the lungs of mice in the treatment group than those of the untreated group, indicating inhibition of metastasis by pSPB-shCD59/VLPs. Together, these results demonstrate the potential of pSPB-shCD59/VLPs as a therapeutic agent for CD59 overexpressed lung cancer. © 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society. |
| URI: | https://ir.csmu.edu.tw:8080/ir/handle/310902500/20472 |
| Relation: | Clinical science (London, England : 1979), Volume 133, Issue 21, Pages 2159-2169 |
| Appears in Collections: | [附設醫院] 期刊論文
|
Files in This Item:
There are no files associated with this item.
|
All items in CSMUIR are protected by copyright, with all rights reserved.
|
